ARTIDIS enters clinical collaboration to investigate nanomechanical profiling as a novel diagnostic and treatment optimization approach in patients with lung cancer


Basel, Switzerland, May 4, 2021– ARTIDIS AG, a privately held health-tech company, announces a collaboration with Hospital Clínic de Barcelona and the University of Barcelona to investigate the ARTIDIS AFM technology as a novel diagnostictool for patients with non-small cell lung carcinoma (NSCLC), the most frequent type of lung cancer. The research partnerswill identify biomarkers that will enable fast and accurate lung cancer diagnosisin a clinical bedside setting. Based on the combinationof results from these novel nanomechanical signatures with additional patient information in the ARTIDISNet platform, a targeted and individualized treatment approachfor each patient can be identified.

In this research collaboration, ARTIDIS and teams from the University of Barcelona and Hospital Clínic de Barcelona will perform comparative analyses of nanomechanical profiles of cancer tissue and sub-cellular components, i.e. tumor microenvironments (TME), in human lung biopsies of patients with NSCLC undergoing surgery at the Hospital Clinic of Barcelona. The teams will use the proprietary ARTIDIS technology that provides nanomechanical profiling, based on atomic force microscopy of patient-derived tissues directly at the patient’s bedside, and combines it with extensive clinical information to deliver fast diagnosis and optimized treatment plans. This 18-month study aims at identifying distinct nanomechanical signatures of major histological subtypes of NSCLC as well as their genetic and immune phenotype (‘hot’ and ‘cold’ tumor). Beyond that, the study aims to show that nanomechanical profiling may be a suitable diagnostic approach in lung cancer with advantages over existing methods, including fast diagnostic assessment, increased accuracy and high specificity with a low proportion of false positives, and could contribute to an early evaluation of the expected treatment response. The results of this collaboration will have a major impact on the information available to help to select the best treatment option for lung cancer patients.

“Physicists and engineers have long used atomic force microscopy to unravel the aberrant mechanobiology of preclinical models of cancer in laboratory settings. Now we bring ARTIDIS’ exciting technology to the clinic to investigate and identify novel nanomechanical biomarkers with the ultimate goal of enabling better treatment outcomes through optimized diagnosis and more guided therapeutic selections,” said Dr. Jordi Alcaraz, Associate Professor at the School of Medicine, University of Barcelona (UB) and associate group leader at the Institute for Bioengineering of Catalonia (IBEC).

“Although the survival of cancer patients has improved thanks to the introduction of targeted therapies, we still need better tools to predict treatment response. In this collaboration, we expect to define tailor-made therapies by classifying cancer subtypes, based on nanomechanical profiles of tumor cells and their microenvironment established using atomic force microscopy, and merging these findings with the patient’s clinical data from his/her own medical history. Ultimately, we aim at providing personalized treatments for cancer patients which will hopefully contribute to better outcomes,” added Dr. Noemi Reguart, Medical Oncologist at the Hospital Clínic de Barcelona (HCB).

“Our collaboration with some of Europe’s leading research and healthcare centers will provide invaluable insight into the nanomechanical features and the treatment of NSCLC,” said Marija Plodinec, Ph.D., CEO at ARTIDIS. “It will establish nanomechanical signatures as key biomarkers in lung cancer and will allow to differentiate NSCLC subtypes and immune phenotypes. I am very excited about the perspectives our ARTIDISNet digital platform offers by combining such findings with the patient case history to establish comprehensive personal disease profiles. Our goal is to provide oncologists with a superior diagnostic approach in NSCLC that will guide patient stratification and will support them in making the best choice for successful treatment optimization for each individual patient.”

This collaboration is bringing ARTIDIS’ unique capabilities for measuring the physical aspects of biological tissue at the molecular level together with the profound expertise of the research group of Dr. Alcaraz at the UB on AFM mechanical measurements of cells and tissues, and that of the clinical group of Dr. Reguart at the HCB on the molecular analysis and diagnosis of lung cancer.

The research builds on previous ARTIDIS data, which has shown that mechanical alterations at the sub-cellular level (in nanoscale resolution) in cancer are potentially suitable markers of cancer aggressiveness and indicators for treatment response [1]. This finding was clinically validated in a prospective study in 545 breast cancer patients, where nanomechanical profiling was used to distinguish subtypes of cancerous lesions with the goal of stratifying high and low risk patients for developing metastases [2]. Moreover, ARTIDIS results suggest that nanomechanical changes in response to treatment may predict responder rate and outcome [2].

Lung cancer is one of the most common cancers and the leading cause of cancer-related death worldwide. Major reasons underlying this high mortality rate are late diagnosis and lacking methods to effectively stratify patients into distinct risk outcome groups, coupled with limited treatment options and very poor prognosis overall. The currently available diagnostic tools in lung cancer include various imaging modalities, histopathological tumor subtyping and molecular profiling of tumor biopsies. Molecular testing at the time of diagnosis also guides therapy selection, and targeted therapies in patients with several actionable genetic alterations (such as EGFR, ALK, ROS, BRAF, NTRK) are nowadays part of routine clinical management. Immunotherapy represents one of the most promising therapeutic approaches in lung cancer and evaluation of immune markers such as PD-L1 is also required at diagnosis to identify those NSCLC patients who most benefit from treatment. However, only ≤20% of lung cancer patients will respond overall underscoring the urgent need for improved methods for fast and early detection while supporting personalized treatment approaches.

[1]  Plodinec, Loparic et al. Nat Nanotechnol. 2012 Nov;7(11):757-65. Link
[2]  Burian et al. AACR Annual Meeting 2020, abstract LB-273. Link

About Hospital Clínic de Barcelona
Hospital Clínic of Barcelona is a public university hospital with a centuries-long history. With 4500 employees, it is one of the leading healthcare centers in Spain and the first in scientific production. The hospital offers quality care, high-level excellence, and competitive biomedical research and a strong teaching commitment to train professionals. All of this is included in an excellent balanced management with the aim of offering society a humanized, cutting-edge medicine.

About University of Barcelona
Founded in 1450, the University of Barcelona is the major public university in Catalonia and one of the most prestigious higher education institutions in Spain. The Bosch i Gimpera Foundation (FBG) is the technology transfer and innovation unit of the University of Barcelona. The FBG is responsible for transferring the results of the research carried out at the UB to society through the creation of spin-offs, patent licensing, and contracts with companies and institutions, thus contributing to the competitiveness of the business framework and the improvement of social welfare. In 2020, has developed 720 projects and contracted € 41.93 million. During the period 2018 - 2020, 51 technologies have been licensed and 8 spin-offs created.

ARTIDIS AG is a clinical stage health-tech company located in Basel, Switzerland, that has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. The ARTIDIS nanotechnology platform integrates the mechanical biomarker data and different types of clinical data into the ARTIDISNet digital platform, allowing physicians to significantly shorten bedside biopsy analysis to less than three hours, enabling personalized disease prognosis and aiding with treatment optimization, thereby bringing benefit to both the patient and the healthcare system. Investigated initially in breast, lung, and pancreatic cancer, the ARTIDIS applications are not limited to oncology, and its nanotechnology platform can be used to analyze any kind of living tissue. For more information please visit

For further information please contact:
Dr. Marija Plodinec, CEO
Phone: +41 61 633 29 95


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novo Nordisk A/S – Share repurchase programme7.5.2021 21:31:30 CEST | Press release

Bagsværd, Denmark, 7May2021 — As part of the up to DKK 18 billion 2021 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to DKK 3.3 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). For that purpose, Novo Nordisk A/S has appointed Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB, as lead manager to execute the programme independently and without influence from Novo Nordisk A/S. The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. Under the agreement, Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB, will repurchase B shares on behalf of Novo Nordisk A/S during the trading period starting 10 May 20

Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme7.5.2021 21:24:00 CEST | Press release

Bagsværd, Denmark, 7 May2021 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’ 2021 share repurchase programme of up to a total of DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. The transaction price is DKK 461.04 per share and has been calculated as the three-day volume weighted average market price from 5 May 2021 to 7 May 2021 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results. Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.5% of the share capital and 76.9% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 116,129,000 B shares of DKK 0.20, corresponding to 28.3% of the capital and 76.8% of the votes in Novo Nordisk A/S. The transaction is in line with the announcement

RomReal: Mandatory notification of insider trade - Chairman and CEO of RomReal Kjetil Gronskag7.5.2021 19:34:48 CEST | Press release

Kjetil Gronskag, Chairman and CEO of RomReal Ltd has today 07 May 2021, purchased 2000 shares of RomReal at NOK 1.74 per share in RomReal Ltd. Following this trade, Kjetil Gronskag controls privately and through holding companies 4,546,127 shares in RomReal Ltd. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

PRFOODS NOTICE OF NOTEHOLDERS’ MEETING7.5.2021 16:58:01 CEST | Press release

AS PRFoods (registry code 11560713, registered address at Pärnu mnt 141, 11314 Tallinn, Estonia; “PRFoods”) hereby notifies persons holding the notes (the “Noteholders”) of the Issuer, due on 22 January 2025 and bearing ISIN code EE3300001577 (the “Notes”), issued under the Terms and Conditions of Secured Note Issue of AS PRFoods dated 14 January 2020 (which have been amended on 25 February 2020; the “Terms”), of convening a meeting of Noteholders (the “Meeting”). The Meeting will be held on 24 May 2021 at 12:00 (EET) at Peetri 12 (Kai Kunstikeskus), 10415 Tallinn, Estonia. Registration for the Meeting will be open at the venue of the Meeting from 11:00 to 11:45 (EET). The management of PRFoods requests all Noteholders to consider that due to COVID-19 caused by the coronavirus, it is advised to minimise the extent of physical gatherings and the participation therein. For this purpose, the management of PRFoods advises to consider authorising representatives of the collateral agent to p

AS PRFoods is Planning an Issue of Subordinated Convertible Notes and Tap-Issue of Secured Notes7.5.2021 16:44:03 CEST | Press release

THIS NOTICE IS NOT INTENDED FOR PUBLICATION, ALLOCATION OR TRANSMISSION, IN PART OR WHOLLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ELSEWHERE THE DISCLOSURE OR TRANSMISSION OF THIS INFORMATION IS NOT ALLOWED. AS PRFoods (registry code 11560713, “PRFoods”) announces that due to the continuing pandemic caused by COVID-19 and the extraordinary effects the pandemic and the measures implemented to combat the pandemic have had on the economic environment, including on the economic operations of PRFoods during the pending 2020/2021 financial year (i.e. the financial year 01.07.2020 – 30.06.2021), PRFoods deems necessary to reinforce its capital structure for the purposes of ensuring a smoother and faster recovery from the negative impacts caused by COVID-19 in the upcoming 2021/2022 financial year (i.e. financial year 01.07.2021 – 30.06.2022). In connection with the above, PRFoods hereby informs that, for the


Bid procedure, 2021-05-12BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: ELLEVIO AB: XS1562583937, 2024-02-28 HUSQVARNA AB: SE0013359486, 2024-12-04 HUSQVARNA AB: SE0010869677, 2023-02-14 LUNDBERGFORETAGEN AB: SE0012676609, 2025-11-13 LUNDBERGFORETAGEN AB: SE0009241524, 2023-10-24 WILLHEM AB: SE0012193985, 2025-02-22 WILLHEM AB: SE0013882966, 2024-04-08 CASTELLUM AB: SE0011062827, 2023-05-17 CASTELLUM AB: SE0012675916, 2025-11-27 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2021-04-12Bid date2021-05-12Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS1562583937: 30 mln SEK +/-30 mln SEK SE0013359486: 30 mln SEK +/-30 mln SEK SE0010869677: 30 mln SEK +/-30 mln SEK SE0012676609: 30 mln SEK +/-30 ml


Bid procedure, 2021-05-14BondsSWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01 SWEDEN I/L BOND: 3111, SE0007045745, 2032-06-01 Bid date2021-05-14Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3113: 500 mln SEK +/-250 mln SEK 3111: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)3113: 500 mln SEK per bid 3111: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-05-18Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-05-07 This is a translation of the special terms and conditions published on In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be